action of glp 1 agonist GLP-1 Agonists “Weighing In” on GLP-1 Receptor

However, there was progress in the UK where the government announced Scotland CardioMetabolic Impact Study (SCoMIS) , a pioneering Real-World study, which will provide Wegovy to between 3,000-5,000 people living with Obesity in Scotlands poorest areas free of charge during a three year study [11] Despite FDA phasing out enforcement discretion that allowed GLP-1 compounding during shortages - and setting May 2025 deadlines for compounding to cease - compounding has continued beyond this deadline [12]

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved a new indication for Wegovy (semaglutide) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes.

Alpha-Lipoic Acid (ALA) adds antioxidant and metabolic support, assisting the bodys ability to utilize glucose more efficiently and support cellular energy production.*

However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the importance that pharmacological treatment of type 2 diabetes mellitus provides not only glycemic control, but also cardiovascular safety

Primary outcomes included changes in TTR, INR, and INR recheck frequency

no major safety concerns were observed